EPRSQ EPIRUS Biopharmaceuticals Inc (CE)

(Amendment No. 2)*

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO 240.13d-2(a)

(Name of Issuer)

(Title of Class of Securities)

(CUSIP Number)

(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)

(Date of Event Which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. o

Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

2

3

This Amendment No. 2 (this “Amendment”) amends and supplements the Schedule 13D filed by the Reporting Persons on July 25, 2014 (the “Original Schedule 13D” and, as amended and supplemented by Amendment No. 1, filed by the Reporting Persons on February 6, 2015, the “Schedule 13D”) with respect to the Common Stock of the Issuer. Capitalized terms used in this Amendment and not otherwise defined shall have the same meanings ascribed to them in the Original Schedule 13D.

Item 4.                             Purpose of Transaction.

Item 4 of the Schedule 13D is hereby amended and supplemented by adding the following paragraphs at the end of Item 4:

Montreux Equity Partners IV, L.P. sold an aggregate of 1,324,758 shares of Common Stock in open market transactions from March 16, 2015 through June 15, 2015.

Montreux Equity Partners V, L.P. sold an aggregate of 255,317 shares of Common Stock in open market transactions from March 4, 2015 through June 15, 2015.

Item 5.                             Interest in Securities of the Issuer.

Item 5 of the Schedule 13D is hereby amended and restated in its entirety as follows:

(a)-(b) The following information with respect to the ownership of the Common Stock of the Issuer by the persons filing this Schedule 13D is provided as of June 15, 2015:

(1) John J. Savarese, M.D., Howard D. Palefsky and Daniel K. Turner III are the managers of Montreux Equity Management IV, LLC, which is the sole general partner of Montreux Equity Partners IV, L.P., which directly holds 346,641 shares of Common Stock of the Issuer.

(2) Daniel K. Turner III is the sole manager of Montreux Equity Management V, LLC, which is the sole general partner of Montreux Equity Partners V, L.P., which directly holds 16,159 shares of Common Stock of the Issuer.

(3) The securities reported herein reflect the 1-for-10 reverse stock split effected by the Issuer on July 16, 2014.

(4) This percentage is calculated based upon 23,514,851 shares of Common Stock outstanding (as of May 11, 2015) as set forth in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 13, 2015.

(c) The Reporting Persons sold the following shares of Common Stock in open market transactions during the 60 days preceding the date of the cover of this Amendment:

4

(1)                     The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.23 to $9.57, inclusive.

(2)                     The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.24 to $9.55, inclusive.

(3)                     The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.20 to $9.28, inclusive.

(4)                     The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.80 to $8.98, inclusive.

5

(5)                     The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.00 to $9.155, inclusive.

(6)                     The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.80 to $9.05, inclusive.

(7)                     The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.80 to $8.83, inclusive.

(8)                     The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.80 to $9.0906, inclusive.

(9)                     The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.50 to $7.84, inclusive.

(10)              The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.50 to $7.60, inclusive.

(11)              The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.75 to $5.92, inclusive.

(12)              The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.75 to $5.89, inclusive.

(13)              The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.40 to $5.97, inclusive.

(14)              The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.80 to $6.12, inclusive.

(15)              The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.80 to $5.81, inclusive.

(16)              The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.60 to $5.89, inclusive.

(17)              The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.40 to $5.555, inclusive.

(18)              The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.75 to $6.00, inclusive.

(19)              The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from$5.50 to $5.78, inclusive.

(20)              The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.26 to $5.55, inclusive.

(21)              The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.56 to $6.04, inclusive.

(22)              The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.81 to $7.14, inclusive.

(23)              The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.63 to $7.835, inclusive.

(24)              The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.33 to $6.385, inclusive.

(25)              The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.20 to $6.30, inclusive.

(26)              The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.00 to $6.05, inclusive.

(27)              The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.90 to $5.94, inclusive.

(28)              The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.00 to $6.05, inclusive.

(29)              The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.70 to $5.76, inclusive

(d) Not applicable.

(e) MEP IV ceased to be the beneficial owner of more than five percent of the Common Stock of the Issuer on April 6, 2015. As of such date, neither of the Reporting Persons was a beneficial owner of more than five percent of the Common Stock of the Issuer.

6

Signature

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

7